Horizon Therapeutics Announces 79% Of Patients Achieved A Complete Response In MIRROR Open-Label Pilot Study, Supporting KRYSTEXXA Immunomodulation Strategy To Optimize Treatment Outcomes
Benzinga Newsdesk